ライフサイエンスコーパス: vaccinia virus

1 the movement of microbial pathogens such as vaccinia virus.

2 athway components for cell-to-cell spread of vaccinia virus.

3 mory CD8(+) T cells following infection with vaccinia virus.

4 sing data from humans, domestic pigeons, and vaccinia virus.

5 the crystal structure of the H7 protein from vaccinia virus.

6 g during a severe respiratory infection with vaccinia virus.

7 and in vivo, during immune responses against vaccinia virus.

8 r HSV-1 were identical to those observed for vaccinia virus.

9 scent formation, including the A6 protein of vaccinia virus.

10 merous RNA viruses but enhances the entry of vaccinia virus.

11 ized against foreign rhesus D alloantigen or vaccinia virus.

12 uitment of leukocytes, which is unique among vaccinia viruses.

13 ll function in the lung after infection with vaccinia virus, a member of the Poxviridae family.

14 immune-deficient (nu/nu) mice infected with vaccinia virus, a model of smallpox.

15 at causes a persistent/latent infection, and vaccinia virus, a poxvirus that is cleared by the host.

16 The vaccinia virus A56 and K2 proteins in the cell membrane

17 In this study, we uncovered a means of vaccinia virus adaptation involving the accumulation of

18 e-prototype JX-594), a replication-competent vaccinia virus administered by intravenous injection, to

19 res of the antitumor properties of oncolytic vaccinia viruses, all of which can be amplified by the m

20 steria monocytogenes, Shigella flexneri, and Vaccinia virus among other pathogens use the same common

21 es of fatty acid in the diet on infection by vaccinia virus, an acute infection that begins in the re

22 It is not enriched for vaccinia virus and Candida albicans-MP65 (immunodominant

23 oping potent neutralizing antibodies against vaccinia virus and comprehensively characterizing their

24 e membrane-wrapping step in morphogenesis of vaccinia virus and egress from the cell.

25 panied by increased viral resistance against vaccinia virus and influenza B virus infections.

26 res are also induced by two other pathogens (vaccinia virus and Listeria monocytogenes).

27 dentical recombinant proteins expressed from vaccinia virus and Listeria monocytogenes.

28 its actin polymerization downstream of EPEC, Vaccinia virus and opsonized red blood cells.

29 Efficient cell-to-cell spread of vaccinia virus and other orthopoxviruses depends on the

30 bisbenzimide derivatives are potent against vaccinia virus and other poxviruses but ineffective agai

31 Vaccinia virus and other poxviruses encode enzymes for b

32 bility to monkeypox virus, cowpox virus, and vaccinia virus and thus providing a unique model for stu

33 r of the Orthopoxvirus genus, which includes Vaccinia virus and Variola virus (the causative agent of

34 rus is intermediate in pathogenicity between vaccinia virus and variola virus.

35 vo from mRNA synthesized in the cytoplasm by vaccinia virus, and hence cannot be spliced.

36 ypox virus, the vaccine and zoonotic species vaccinia virus, and the mouse pathogen ectromelia virus

37 uential immunizations with DNA (D), modified vaccinia virus Ankara (MVA) (M), and protein immunogens,

38 The clinically relevant vectors modified vaccinia virus Ankara (MVA) and the chimpanzee adenoviru

39 impanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) and used to immunize mice in

40 Using a modified vaccinia virus Ankara (MVA) as a vaccine model, we chara

41 A DNA prime-modified vaccinia virus Ankara (MVA) boost vaccine has proven to

42 priming with DNA and boosting with modified vaccinia virus Ankara (MVA) expressing HIV-1 Env on viru

43 Modified vaccinia virus Ankara (MVA) is a safe and well-character

44 asal administration of the poxvirus modified vaccinia virus Ankara (MVA) is sufficient to induce high

45 ctors simian adenovirus 63 (ChAd63)-modified vaccinia virus Ankara (MVA) is the most potent inducer o

46 h either recombinant DNA (n = 4) or modified vaccinia virus Ankara (MVA) poxvirus vector (n = 4) expr

47 we show that a CD40L-adjuvanted DNA/modified vaccinia virus Ankara (MVA) simian immunodeficiency viru

48 M1L is absent in the attenuated modified vaccinia virus Ankara (MVA) strain of VACV, a strain tha

49 We have constructed a recombinant modified vaccinia virus Ankara (MVA) that expresses an H5N1 mosai

50 to adjuvant the DNA prime of a DNA/modified vaccinia virus Ankara (MVA) vaccine in rhesus macaques.

51 ity to both insert Ag85A and vector modified vaccinia virus Ankara (MVA) was assessed by ex-vivo inte

52 The poxvirus strain modified vaccinia virus Ankara (MVA), a safe and efficient viral

53 ific T cells induced by a DNA-prime modified vaccinia virus Ankara (MVA)-boost vaccination strategy,

54 Modified vaccinia virus Ankara (MVA)-encoding antigens are consid

55 virus (SIV) challenges in seven DNA/modified vaccinia virus Ankara (MVA)-vaccinated rhesus macaques w

56 onserved antigenic regions by using modified vaccinia virus Ankara (MVA).

57 sized and cloned into a recombinant modified vaccinia virus Ankara (MVA).

58 /IL-15, SIV Gag/Pol/Env recombinant modified vaccinia virus Ankara (rMVA), and AT-2 SIVmac239 inactiv

59 (IL-2), and IL-15 DNAs, recombinant modified vaccinia virus Ankara (rMVA), and inactivated SIVmac239

60 imate model that vaccination with a modified vaccinia virus Ankara encoding hemagglutinin from a hete

61 Modified vaccinia virus Ankara expressing antigen 85A (MVA85A) is

62 f a candidate tuberculosis vaccine, modified vaccinia virus Ankara expressing antigen 85A (MVA85A), i

63 We show that booster modified vaccinia virus Ankara immunization induced a distinct an

64 e questions in the context of a DNA/modified vaccinia virus Ankara SIV vaccine with and without gp140

65 teins (ChronVac-C) and boost with a modified vaccinia virus Ankara vaccine expressing genotype 1b NS3

66 r SIVmac239 envelope-expressing DNA/modified vaccinia virus Ankara vector- and protein-based vaccinat

67 oost regimen with a mixture of MVA (Modified Vaccinia virus Ankara) and Ad5 (human adenovirus type 5)

68 far, well-described vectors such as modified vaccinia virus Ankara, complex adenovirus, vesicular sto

69 impanzee adenovirus 63, ChAd63, and modified vaccinia virus Ankara, MVA, expressing AgAPN1, Pfs230-C,

70 ized with SIVmac239-based DNA-prime/modified vaccinia virus Ankara-boost vaccine regimens that includ

71 Modified vaccinia virus Ankara-ovalbumin (MVA-OVA) vaccination in

72 ther a chimpanzee adenovirus 63 and modified vaccinia virus Ankara-vectored vaccine expressing a mult

73 second homologous immunization with modified vaccinia virus Ankara.

74 lfolobus spindle-shaped virus Kamchatka, and vaccinia virus are reversibly inactivated by mineralizat

75 artments, made possible by using cytoplasmic vaccinia virus as a carrier for the AAV helper genes.

76 as been developed using the immunogenic live vaccinia virus as a vaccine vector, expressing multiple

77 odulated the infectious dose of the poxvirus vaccinia virus as an approach to modulate the environmen

78 protein toxins, potently prevented spread of vaccinia virus as well as monkeypox virus, a human patho

79 we present the crystal structure of H3 from vaccinia virus at a 1.9-A resolution.

80 and ovarian cancer models that an oncolytic vaccinia virus attracts effector T cells and induces PD-

81 t that dynamic phosphorylation involving the vaccinia virus B1 kinase and cellular enzymes is likely

82 The vaccinia virus B1 kinase is highly conserved among poxvi

83 The most well characterized role for the vaccinia virus B1 kinase is to facilitate viral DNA repl

84 The vaccinia virus B1 protein is a homolog of cellular vacci

85 HIV-1 antigens, with one of them lacking the vaccinia virus B19 protein, an inhibitor of the type I i

86 The vaccinia virus B1R gene encodes a highly conserved prote

87 TRAP is delivered using adenovirus- and vaccinia virus-based vectors in a prime-boost regime.

88 accination of rhesus monkeys compared to the vaccinia virus-based vectors MVA and NYVAC.

89 Although superinfecting vaccinia virus bound to cells, infection was inhibited a

90 immunization with Plasmodium sporozoites or vaccinia virus, but a few weeks later their numbers seve

91 onocytogenes, vesicular stomatitis virus, or Vaccinia virus, but dispensable in the case of mouse cyt

92 gression are arrested in cells infected with vaccinia virus, but mass fluctuations continue until cel

93 uperinfection exclusion may be beneficial to vaccinia virus by selecting particles that can infect ce

94 host-range proteins that share homology with vaccinia virus C7 protein.

95 on of oncolytic parapoxvirus ovis (ORFV) and vaccinia virus can reverse NK cell suppression, which co

96 red improved protection against Listeria and vaccinia virus challenges compared with the Armstrong bo

97 Thus, vDeltaK1L is the first vaccinia virus construct reported that caused a muted in

98 ispensable for determining the mechanisms of vaccinia virus core-directed transcription.

99 Thus, vaccinia virus decapping, in addition to targeting mRNAs

100 XCR4 antagonist expression from an oncolytic vaccinia virus delivered intravenously to mice with orth

101 n a murine model of cutaneous infection with vaccinia virus, dermal gammadelta T cell numbers increas

102 ptimal control of Listeria monocytogenes and vaccinia virus, despite weak recall proliferative respon

103 ith preexisting airway disease infected with vaccinia virus developed more severe pulmonary inflammat

104 Vaccinia virus dissemination relies on the N-WASP-ARP2/3

105 nsight into the role of D4 as a co-factor of vaccinia virus DNA polymerase and allows a better unders

106 Vaccinia virus early genes are transcribed immediately u

107 Because vaccinia virus early transcription is coupled to the vir

108 Immunization with vaccinia virus elicits a protective Ab response that is

109 virion preparations, >88% of the theoretical vaccinia virus-encoded proteome was detected with high c

110 The A19L open reading frame of vaccinia virus encodes a 9-kDa protein that is conserved

111 Vaccinia virus encodes a number of proteins that inhibit

112 EPD of vaccinia virus encoding OVA induced significantly higher

113 gainst intranasal challenge with recombinant vaccinia virus encoding p24.

114 peptide-pulsed dendritic cells, recombinant vaccinia viruses encoding full-length T Ag or epitope mi

115 Comparison of responses to vaccinia virus expressing OVA peptide SIINFEKL by wild-t

116 vides complete immune control of recombinant vaccinia virus expressing the same epitope if KCSRNRQYL

117 and was phosphorylated independently of the vaccinia virus F10 kinase.

118 aa 21-84), a recombinant envelope protein of vaccinia virus, for glycosaminoglycans (GAGs)-specific t

119 CD8(+) T cells act synergistically to clear vaccinia virus from a primary skin infection.

120 ed RNA start sites have made the analysis of vaccinia virus gene expression challenging.

121 rhtrs1-amplified viruses, there arose in two vaccinia virus genes mutations that improved viral repli

122 t on the rapid positive selection of a novel vaccinia virus genomic duplication mutant in the presenc

123 ed interactions between genetically-modified vaccinia virus (GLV-1h68) and radiotherapy in melanoma c

124 fficacy of a replication-competent oncolytic vaccinia virus, GLV-1h153, carrying human sodium iodide

125 We demonstrated that a novel vaccinia virus, GLV-1h153, expresses hNIS, increases the

126 omologs of the Bcl-2 family of proteins, and vaccinia virus harbors antiapoptotic F1L that potently i

127 The smallpox vaccine using vaccinia virus has been highly successful, but it is sti

128 modified by the insertion of the K1L and C7L vaccinia virus host range genes and express the clade C(

129 per by applying it to SIM and STED images of vaccinia virus in isolation and when engaged with host c

130 ges in the cytoskeleton, studies with mutant vaccinia viruses indicated that the cytoskeletal changes

131 RNAs were translationally upregulated during vaccinia virus-induced host protein synthesis shutoff.

132 ured the host mRNA translation rate during a vaccinia virus-induced host shutoff by analyzing total a

133 ns may be selectively synthesized during the vaccinia virus-induced host shutoff.

134 h we previously reported an association with vaccinia virus-induced neutralizing antibody titers in t

135 , we analyzed the responses of host cells to vaccinia virus infection at both the transcriptional and

136 minor groove of double-stranded DNA, inhibit vaccinia virus infection by blocking viral DNA replicati

137 This study highlights the fact that vaccinia virus infection can enhance cellular energy pro

138 Vaccinia virus infection causes a host shutoff that is m

139 Using a model of respiratory vaccinia virus infection in mice, we could specifically

140 In this study, with vaccinia virus infection in mice, we show that OX40 was

141 ease on the host response to intra-pulmonary vaccinia virus infection remain poorly defined.

142 dependent of infection or during a surrogate vaccinia virus infection to identify how MC159 prevented

143 infection with either virus, after a cleared vaccinia virus infection, and during a persistent/latent

144 f oxidative phosphorylation increased during vaccinia virus infection, while inhibition of the cellul

145 regulation of the CD8(+) T cell response to vaccinia virus infection.

146 ncreased and accelerated mortality following vaccinia virus infection.

147 most bone marrow T cells activate 3 d after vaccinia virus infection.

148 dly increase translation in the first day of vaccinia virus infection.

149 LECs toward MPECs, during the acute phase of vaccinia virus infection.

150 ty to localize infected cells and to control vaccinia virus infection.

151 which accelerates clearance of epicutaneous vaccinia virus infection.

152 e ability to act as a potent defense against vaccinia virus infection.

153 in a cell-intrinsic manner in the context of vaccinia virus infection.

154 cific CD8(+) T cells responses to subsequent vaccinia virus infection.

155 mune detection pathways, we performed serial vaccinia virus infections in primary human cells.

156 hat, to display robust actin-based motility, vaccinia virus integrates the activity of the N-WASP-ARP

157 Vaccinia virus is a powerful model to study antibody res

158 nd vaccination of patients with AD with live vaccinia virus is contraindicated because of a heightene

159 present evidence that the impact of VRK2 on vaccinia virus is largely independent of BAF phosphoryla

160 on, and in the case of influenza B virus and vaccinia virus, ISG15 conjugation has been shown to rest

161 Until now, all known rifampin-resistant vaccinia virus isolates have contained missense mutation

162 On the basis of these results, vaccinia virus keratitis is significantly different from

163 We found a site in vaccinia virus L1 protein as the target of a group of hi

164 nd D10, but not of either enzyme alone, halt vaccinia virus late protein synthesis and inhibit virus

165 that B1 is required at another stage of the vaccinia virus life cycle.

166 Thus, vaccinia virus makes novel use of the retrograde transpo

167 nd we show for the first time that oncolytic vaccinia virus markedly increases NK cell activity in pa

168 Vaccinia virus membrane biogenesis requires the A14 and

169 sion in other viral systems, did not prevent vaccinia virus membrane fusion, suggesting that these in

170 Upon infections with Toxoplasma gondii and vaccinia virus, mice with stabilized DC beta-catenin dis

171 revealed that this protein is essential for vaccinia virus morphogenesis and that its absence result

172 ract of inflamed rabbit skin inoculated with vaccinia virus (Neurotropin((R))) enhanced efficiency of

173 The vaccinia virus nucleocapsid has been neglected since the

174 of high-pressure freezing in preserving the vaccinia virus nucleocapsid.

175 We characterized a mouse model of vaccinia virus ocular disease using C57BL/6 mice and str

176 of a CXCR4 antagonist expressed by oncolytic vaccinia virus (OVV) against an invasive variant of the

177 virions excluded hundreds of superinfecting vaccinia virus particles.

178 Vaccinia virus polymerase holoenzyme is composed of the

179 adults, with or without immunity to CMV and vaccinia virus (previous DryVax smallpox vaccination).

180 t rabbits immunized with a novel recombinant vaccinia virus prime-gp120 protein boost regimen generat

181 network is also assembled downstream of the Vaccinia virus protein A36 and the phagocytic Fc-gamma r

182 We now demonstrate that the vaccinia virus protein F11, which localizes to the plasm

183 s a constitutively expressed, phosphorylated vaccinia virus protein that has been implicated in viral

184 Ab and CD4(+) T cell responses to particular vaccinia virus proteins suggesting that CD4(+) T cell he

185 Five conserved vaccinia virus proteins, referred to as Viral Membrane A

186 ide evidence for the phosphoglycosylation of vaccinia virus proteins.

187 n and luciferase reporters demonstrated that vaccinia virus recognized MOCV intermediate and late pro

188 ia virus B1 protein is a homolog of cellular vaccinia virus-related kinases (VRKs) and is needed for

189 xhibits a remarkable degree of similarity to vaccinia virus-related kinases (VRKs), a family of cellu

190 25 enhances herpes simplex virus (HSV)-1 and vaccinia virus replication by inhibiting filaggrin expre

191 depend on host cells to provide, to support vaccinia virus replication during a host shutoff.IMPORTA

192 iscovered that TRAF2 is a proviral factor in vaccinia virus replication in both HeLa cells and mouse

193 ver, Ripk1(D138N/D138N) mice fail to control vaccinia virus replication in vivo.

194 the beginning of the 1980s, research on the vaccinia virus replication mechanism has basically stall

195 maintenance of its function is important for vaccinia virus replication.

196 horylation function significantly suppressed vaccinia virus replication.

197 o dual-specificity phosphatase (DUSP) VH1 of vaccinia virus revealed that VH1 is highly active toward

198 Vaccinia virus ribosome-associated mRNA sequences were d

199 icited against allogeneic RhD+ erythrocytes, vaccinia virus, rotavirus, or tetanus toxoid provides ev

200 perator sequence) into oncolytic recombinant vaccinia viruses (rVACV), which were further characteriz

201 owed by intranasal boosting with recombinant vaccinia virus (rVV) encoding S436 or S525 resulted in a

202 n blood, throat swabs, and selected tissues, vaccinia virus-specific antibody responses, immunophenot

203 Poxviruses, myxoma virus and vaccinia virus specifically, utilize a virus-encoded hos

204 ection of C57BL/6 mice with 1 x 10(7) PFU of vaccinia virus strain WR results in blepharitis, corneal

205 or two genes into the genome of an oncolytic vaccinia virus strain.

206 c single chain antibodies by using oncolytic vaccinia virus strains to enhance their therapeutic effi

207 e B21/22 family glycoproteins not encoded by vaccinia virus strains used as vaccines.

208 In this study, we show across a range of vaccinia virus strains, including the current clonal sma

209 ved in isolates from an outbreak of zoonotic vaccinia virus that occurred in Brazil.

210 Vaccinia virus, the live vaccine for smallpox, is one of

211 When compared to vaccinia virus, this archival strain contained the same

212 antiviral protein PKR, enabled a recombinant vaccinia virus to replicate in resistant cells from huma

213 here that this expanded tropism of oncolytic vaccinia virus to the endothelial compartment is a conse

214 During its egress, vaccinia virus transiently recruits AP-2 and clathrin af

215 uct a high-resolution genome-wide map of the vaccinia virus translatome.

216 Respiratory vaccinia virus transmission is well established, yet the

217 d virus-specific IgG1 levels were reduced in vaccinia virus-treated mice with IL-10 receptor blockade

218 e inhibitor 1 (SPI-1) of rabbitpox virus and vaccinia virus, two closely related orthopoxviruses, pre

219 Vaccinia virus (VACV) A27 is a target for viral neutrali

220 A Vaccinia virus (VACV) B-cell CLL/lymphoma 2 (Bcl-2) homo

221 In this study, we applied vaccinia virus (VACV) by scarification to IL-1R1 knockou

222 Vaccinia virus (VACV) continues to be used in immunother

223 produced in excess in cells infected with a vaccinia virus (VACV) decapping enzyme mutant and by wil

224 Vaccinia virus (VACV) decapping enzymes and cellular exo

225 The vaccinia virus (VACV) E3 protein has been shown to be im

226 The I2L open reading frame of vaccinia virus (VACV) encodes a conserved 72-amino-acid

227 Vaccinia virus (VACV) encodes an innate immune evasion p

228 The poxvirus vaccinia virus (VACV) encodes numerous inhibitors of NF-

229 Vaccinia virus (VACV) encodes several proteins that inhi

230 Vaccinia virus (VacV) encodes two decapping enzymes (D9,

231 Vaccinia virus (VACV) envelope protein D8 is one of thre

232 This work reveals the prototypic poxvirus Vaccinia virus (VACV) exploits cellular retrograde trans

233 ses; instead, we identified mutations in two vaccinia virus (VACV) genes, A24R and A35R, either of wh

234 have determined the crystal structure of the vaccinia virus (VACV) H7 protein.

235 assessed several routes of immunization with vaccinia virus (VACV) in protecting mice against ectrome

236 This study investigates how vaccinia virus (VACV) infection alters global cellular m

237 -knockout CD8(+) TRM cells generated by skin vaccinia virus (VACV) infection were less effective at p

238 In establishing a respiratory infection, vaccinia virus (VACV) initially replicates in airway epi

239 Vaccinia virus (VACV) is a member of the Poxviridae fami

240 Vaccinia virus (VACV) is a poxvirus, and the VACV D4 pro

241 Vaccinia virus (VACV) is a useful model system for under

242 Skin scarification (s.s.) with vaccinia virus (VACV) is essential for generation of an

243 The extracellular virion form (EV) of vaccinia virus (VACV) is essential for viral pathogenesi

244 The vaccinia virus (VACV) K1 protein has multiple immunomodu

245 elicited protective immunity.IMPORTANCE The vaccinia virus (VACV) K1 protein inhibits NF-kappaB acti

246 Vaccinia virus (VACV) keratitis is a serious complicatio

247 Vaccinia virus (VACV) L1 is an important target for vira

248 The vaccinia virus (VACV) M1 ankyrin (ANK) protein, a protei

249 f a novel apoptosis inhibitor encoded by the vaccinia virus (VACV) M1L gene.

250 Vaccinia virus (VACV) provides the backbone for some of

251 Successful vaccinia virus (VACV) replication in the host requires e

252 PKRs were able to restrict replication of a vaccinia virus (VACV) strain that lacks the PKR inhibito

253 high-throughput RNAi screen directed against vaccinia virus (VACV) to identify the VACV AAA+ ATPase D

254 Poxviruses such as Vaccinia virus (VACV) undertake a complex cytoplasmic re

255 The 50% lethal intraperitoneal dose of vaccinia virus (VACV) was 3 PFU for CAST mice, whereas B

256 ort for the first time that activity against vaccinia virus (VACV) was achieved using novel l-analogu

257 Neutralizing antibodies (NAb) to Vaccinia virus (VACV) were elicited by both doses of MVA

258 virus (ECTV), a natural mouse pathogen, and vaccinia virus (VACV), a heterologous virus that neverth

259 arly every step in the reproductive cycle of vaccinia virus (VACV), a large DNA virus with about 200

260 is overcome when cells are co-infected with vaccinia virus (VACV), a vertebrate DNA virus.

261 Replication-competent viruses, such as Vaccinia virus (VACV), are powerful tools for the develo

262 ified whereby mammalian poxviruses, notably, vaccinia virus (VACV), but also cowpox and myxoma viruse

263 eterminants derived from a complex pathogen, vaccinia virus (VACV), that are presented by the most fr

264 y plasmid can replicate in cells infected by vaccinia virus (VACV), the prototype poxvirus.

265 n of proteins on nascent DNA) to investigate vaccinia virus (VACV), the prototype poxvirus.

266 Immunization with vaccinia virus (VACV), the virus comprising the smallpox

267 Myxoma virus (MYXV) and vaccinia virus (VACV), two distinct members of the famil

268 Yet, in the case of vaccinia virus (VACV), which constitutes the vaccine use

269 We used vaccinia virus (VACV)--a gold standard vaccine--as the i

270 Using skin infections with vaccinia virus (VacV)-expressing model antigens, we foun

271 are antigen-transporting cells that generate vaccinia virus (VACV)-specific T-cell responses, yet how

272 ient (nude, nu/nu) BALB/c mice infected with vaccinia virus (VACV).

273 EdU) into nascent DNA in cells infected with vaccinia virus (VACV).

274 e immunity to a number of viruses, including vaccinia virus (VACV).

275 in the replication of the prototype poxvirus vaccinia virus (VACV).

276 lymphocytic choriomeningitis virus (LCMV) or vaccinia virus (VACV).

277 ted only to exhibit abortive infections with vaccinia virus (VACV).

278 ancer-killing (oncolytic) virus therapy with vaccinia virus (VACV).

279 evealed new insights into the endocytosis of vaccinia virus (VACV).

280 ed among poxviruses, including A6 and A11 of vaccinia virus (VACV).

281 ccination program using different strains of vaccinia virus (VACV; Poxviridae).

282 We determined that a K1L-less vaccinia virus (vDeltaK1L) was less pathogenic than wild

283 deep study of the covalent structure of the vaccinia virus virion using the various tools of contemp

284 xamine the protein covalent structure of the vaccinia virus virion.

285 Poxviruses, including vaccinia virus (VV) and canarypox virus (ALVAC), do not

286 virus-infected cells following epicutaneous vaccinia virus (VV) infection of mice.

287 e epidermis known as eczema vaccinatum after vaccinia virus (VV) infection of the skin.

288 Epicutaneous vaccinia virus (VV) infection, mimicking human smallpox

289 Vaccinia virus (VV) is an enveloped DNA virus from the p

290 a medium-sized (13 kB genome) RNA virus; and vaccinia virus (VV), a large (200 kB genome) DNA virus.

291 Chimpanzee adenovirus-6 (AdC6) or -7 (AdC7), Vaccinia virus (VV), and DNA given by electroporation (D

292 each viral protein in persons immunized with vaccinia virus (VV), either recently or more than 40 yea

293 innate immune control of the infection with vaccinia virus (VV).

294 We report here that the engineered oncolytic vaccinia virus VVWR-TK(-)RR(-)-Fcu1 can induce immunogen

295 el, a new class of potent antivirals against vaccinia virus was designed and synthesized, of which tw

296 We showed that superinfection by vaccinia virus was prevented at the membrane fusion step

297 From our work with vaccinia virus, we give first insights into the overall

298 and long-term memory CD4 T-cell responses to vaccinia virus were mathematically indistinguishable for

299 ymphocytic choriomeningitis virus (LCMV) and vaccinia virus, where the pathogens are cleared, but it

300 sease is induced by intradermal injection of vaccinia virus, whereas a protective response occurs wit